What do systematic reviews say?

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1743 participants
  Low

Silodosin vs tamsulosin

Silodosin probably leads to higher sexual adverse events compared with tamsulosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 6.05 [3.55, 10.31]
  10 studies · 1849 participants
  Moderate

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.25 [0.81, 1.93]
  4 studies · 659 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.41, 2.56]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 5.93 [2.16, 16.29]
  4 studies · 405 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.36, 1.24]
  1 study · 60 participants
  Low

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 820 participants
  Moderate

Silodosin vs alfuzosin

Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 37.21 [5.32, 260.07]
  1 study · 95 participants
  Moderate

Silodosin vs placebo

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with placebo (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.08 [0.7, 1.66]
  3 studies · 1703 participants
  Low

Silodosin vs placebo

It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.28 [0.67, 2.45]
  4 studies · 1967 participants
  Very low

Silodosin vs placebo

Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 26.07 [12.36, 54.97]
  4 studies · 1967 participants
  Moderate

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1708 participants
  Low

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1707 participants
  Low

Silodosin vs tamsulosin

It is very uncertain whether silodosin changes treatment withdrawal due to any reason compared with tamsulosin (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.62, 1.69]
  10 studies · 1573 participants
  Very low

Silodosin vs tamsulosin

Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.53, 1.12]
  11 studies · 1955 participants
  Low